1789 studies found for:    Bevacizumab
Show Display Options
Rank Status Study
1 Completed
Has Results
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
Condition: Diabetic Retinopathy
Interventions: Procedure: Laser Photocoagulation;   Drug: Bevacizumab
2 Completed Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
Condition: Glaucoma
Interventions: Drug: Bevacizumab;   Drug: Mitomycin C
3 Unknown  Intralesional Bevacizumab Injection on Primary Pterygium
Conditions: Pterygium;   Inflammation
Interventions: Drug: Intralesional injection of bevacizumab;   Drug: Topical antihistamine and vasoconstrictor
4 Recruiting Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1
Condition: Retinopathy of Prematurity
Intervention: Procedure: Injection of bevacizumab intravitreal (Avastin)
5 Recruiting Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: TPI 287;   Drug: Bevacizumab
6 Completed Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
Condition: Macular Degeneration
Interventions: Drug: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
7 Recruiting Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Condition: Glioblastoma Multiforme
Interventions: Drug: TPI 287;   Drug: Bevacizumab
8 Completed
Has Results
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Conditions: Carcinoma, Renal Cell;   Adenocarcinoma, Renal Cell;   Nephroid Carcinoma,;   Hypernephroid
Interventions: Drug: RAD001(everolimus);   Drug: interferon alfa-2a;   Drug: bevacizumab
9 Completed Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Vinorelbine;   Drug: Cisplatin;   Drug: Bevacizumab;   Drug: Docetaxel;   Drug: Gemcitabine
10 Completed
Has Results
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: irinotecan hydrochloride;   Biological: bevacizumab;   Drug: temozolomide
11 Recruiting Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
Condition: Brain Cancer
Interventions: Drug: Vorinostat;   Drug: Bevacizumab
12 Recruiting Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Condition: Malignant Glioma (WHO Grade III or IV)
Interventions: Drug: CTO and Bevacizumab;   Drug: CTO alone
13 Unknown  Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Condition: Brain Tumors
Intervention: Drug: Neuradiab in combination with Bevacizumab (Avastin)
14 Active, not recruiting Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Condition: Melanoma
Interventions: Drug: Bevacizumab Plus Ipilimumab Cohort 1;   Drug: Bevacizumab Plus Ipilimumab Cohort 2;   Drug: Bevacizumab Plus Ipilimumab Cohort 3;   Drug: Bevacizumab Plus Ipilimumab Cohort 4
15 Completed
Has Results
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Condition: Adult Solid Tumor
Intervention: Drug: TRC105 and Bevacizumab
16 Active, not recruiting Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
Conditions: Brain Neoplasms;   Central Nervous System Neoplasms
Interventions: Drug: TPI287;   Drug: Bevacizumab
17 Terminated Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
Condition: Toxicity
Intervention: Biological: bevacizumab
18 Active, not recruiting Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Placebo
19 Recruiting Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Conditions: Brain Cancer;   Glioblastoma
Interventions: Drug: Standard Dose Bevacizumab;   Drug: Low Dose Bevacizumab;   Drug: Lomustine
20 Active, not recruiting HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
Conditions: Liver Cancer;   Advanced Cancer
Interventions: Drug: Irinotecan;   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Cetuximab

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years